Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress-mediated cell death in multiple myeloma cells

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 474-486

  Moriya, Shota ^a   Komatsu, Seiichiro ^b   Yamasaki, Kaho ^a   Kawai, Yusuke ^a   Kokuba, Hiroko ^c   Hirota, Ayako ^a   Che, Xiao Fang ^a   Inazu, Masato ^a   Gotoh, Akihiko ^d   Hiramoto, Masaki ^a   Miyazawa, Keisuke ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Breast Oncology Center   (Japan)

^c Electron microscopy center   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

Aggresome; Autophagy; ER stress; Multiple myeloma; Proteasome

Indexed keywords

ALPHA TUBULIN; BORTEZOMIB; CASPASE 3; CELL PROTEIN; CLARITHROMYCIN; DYNEIN ADENOSINE TRIPHOSPHATASE; PROTEASOME; SMALL INTERFERING RNA; VIMENTIN; VORINOSTAT; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HYDROXAMIC ACID; PYRAZINE DERIVATIVE;

AGGRESOME; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL GROWTH; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GENE SILENCING; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MULTIPLE MYELOMA; NERVE CELL NETWORK; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TARGET CELL; UPREGULATION; WILD TYPE; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BORONIC ACIDS; BORTEZOMIB; CELL LINE, TUMOR; CLARITHROMYCIN; DRUG SYNERGISM; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICE; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 84918509818     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2773     Document Type: Article

References (39)

1. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.
2. San Miguel JF , Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906-917, 2008.
3. Richardson PG, Xie W, Jagannath S, et al: A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 123: 1461-1469, 2014.
4. Siegel DS, Martin T, Wang M, et al: A phase 2 study of single-agent carfilzomib (PX-171-003-A 1) in patients with relapsed and refractory multiple myeloma. Blood 120: 2817-2825, 2012.
5. Dimopoulos M, Siegel DS, Lonial S, et al: Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 14: 1129-1140, 2013.
6. Orlowski RZ: Novel agents for multiple myeloma to overcome resistance in phase I clinical trials. Semin Oncol 40: 634-651, 2013.
7. Martinon F: Targeting endoplasmic reticulum signaling pathways in cancer. Acta Oncol 51: 822-830, 2012.
8. Hetz C, Chevet E and Harding HP: Targeting the unfolded protein response in disease. Nat Rev Drug Discov 12: 703-719, 2013.
9. Tabas I and Ron D: Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13: 184-190, 2011.
10. Verfaillie T, Salazar M, Velasco G and Agostinis P: Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol 2010: 930509, 2010.
11. Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075, 2008.
12. Mizushima N: Autophagy in protein and organelle turnover. Cold Spring Harb Symp Quant Biol 76: 397-402, 2011.
13. Kirkin V, McEwan DG, Novak I and Dikic I: A role for ubiquitin in selective autophagy. Mol Cell 34: 259-269, 2009.
14. Korolchuk VI, Menzies FM and Rubinsztein DC: Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FE BS Lett 584: 1393-1398, 2010.
15. Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T, Che XF, Naito M, Itoh M and Tomoda A: Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: Crosstalk among proteasome, autophagy-lysosome and ER stress. Int J Oncol 38: 643-654, 2011.
16. Moriya S, Che XF, Komatsu S, Abe A, Kawaguchi T, Gotoh A, Inazu M, Tomoda A and Miyazawa K: Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol 42: 1541-1550, 2013.
17. Komatsu S, Miyazawa K, Moriya S, Takase A, Naito M, Inazu M, Kohno N, Itoh M and Tomoda A: Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. Int J Oncol 40: 1029-1039, 2012.
18. Simms-W aldrip T, Rodriguez-G onzalez A, Lin T, Ikeda AK, Fu C and Sakamoto KM: The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab 94: 283-286, 2008.
19. Kawaguchi Y, Kovacs JJ , McLaurin A, Vance JM, Ito A and Yao TP: The deacetylase HDAC 6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738, 2003.
20. Ouyang H, Ali YO , Ravichandran M, Dong A, Qiu W, MacKenzie F, Dhe-Paganon S, Arrowsmith CH and Zhai RG : Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. J Biol Chem 287: 2317-2327, 2012.
21. Lee JY , Koga H, Kawaguchi Y, et al: HDAC 6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 29: 969-980, 2010.
22. Fusco C, Micale L, Egorov M, et al: The E3-ubiquitin ligase TRI M50 interacts with HDAC 6 and p62, and promotes the sequestration and clearance of ubiquitinated proteins into the aggresome. PLoS One 7: e40440, 2012.
23. Yan J, Seibenhener ML, Calderilla-Barbosa L, Diaz-Meco MT, Moscat J, Jiang J, Wooten MW and Wooten MC: SQSTM1/p62 interacts with HDAC 6 and regulates deacetylase activity. PLoS One 8: e76016, 2013.
24. Komatsu S, Moriya S, Che XF, Yokoyama T, Kohno N and Miyazawa K: Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochem Biophys Res Commun 437: 41-47, 2013.
25. Olsen EA , Kim YH, Kuzel TM, et al: Phase II b multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T- cell lymphoma. J Clin Oncol 25: 3109-3115, 2007.
26. Kavanaugh SM, White LA and Kolesar JM: Vorinostat: a novel therapy for the treatment of cutaneous T- cell lymphoma. Am J Health Syst Pharm 67: 793-797, 2010.
27. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP: HDAC 6 is a microtubule-associated deacetylase. Nature 417: 455-458, 2002.
28. Haggarty SJ, Koeller KM, Wong JC , Grozinger CM and Schreiber SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC 6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100: 4389-4394, 2003.
29. Garcia-Mata R, Bebök Z, Sorscher EJ and Sztul ES: Characterization and dynamics of aggresome formation by a cytosolic GF P-chimera. J Cell Biol 146: 1239-1254, 1999.
30. Johnston JA , Ward CL and Kopito RR : Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143: 1883-1898, 1998.
31. Hung YH, Chen LM, Yang JY and Yang WY : Spatiotemporally controlled induction of autophagy-mediated lysosome turnover. Nat Commun 4: 2111, 2013.
32. Richter-L andsberg C and Leyk J: Inclusion body formation, macroautophagy, and the role of HDAC 6 in neurodegeneration. Acta Neuropathol 126: 793-807, 2013.
33. Hol EM, Fischer DF, Ovaa H and Scheper W: Ubiquitin proteasome system as a pharmacological target in neurodegeneration. Expert Rev Neurother 6: 1337-1347, 2006.
34. Nawrocki ST, Carew JS, Maclean KH, Courage JF , Huang P, Houghton JA , Cleveland JL , Giles FJ and McConkey DJ: Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 112: 2917-2926, 2008.
35. Zaarur N, Meriin AB, Bejarano E, Xu X, Gabai VL, Cuervo A M and Sherman MY: Proteasome failure promotes positioning of lysosomes around the aggresome via local block of microtubule-dependent transport. Mol Cell Biol 34: 1336-1348, 2014.
36. Nakamura M, Kikukawa Y, Takeya M, Mitsuya H and Hata H: Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 37: 815-820, 2010.
37. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R and Tashiro Y: Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 23: 33-42, 1998.
38. Renna M, Schaffner C, Brown K, et al: Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 121: 3554-3563, 2011.
39. Maejima I, Takahashi A, Omori H, et al: Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J 32: 2336-2347, 2013.